FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056173816> ?p ?o ?g. }

• W2056173816 abstract "Background. Bones constitute the most frequent localization of distant failure in breast cancer patients. Treatment of bone metastases is virtually palliative, but in a proportion of patients can effectively prolong survival and improve quality of life. Currently, there are no effective strategies to prevent bone dissemination with systemic adjuvant therapies. Thus, better molecular selection and identification of patients who have particularly high risk of skeletal metastases may facilitate designing future clinical trials. In this study we analyzed expression of selected tumor proteins potentially associated with skeletal metastases in breast cancer patients. Patients and methods. The study group included 184 metastatic breast cancer patients; 113 with clinically diagnosed bone metastases and 71 with exclusively other sites of metastases, respectively. In all patients, using tissue microarrays technology, IHC expression of the following proteins was evaluated in the primary tumor: estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki67, cyclooxygenase 2 (COX2), chemokine receptor CXCR4, osteopontin (OPN), calcium sensing receptor (CaSR), cytokeratins 5/6 (CK5/6) and parathyroid hormone-related protein receptor 1 (PTHrPR1). Additionally based on ER/PR, HER2 and Ki67 expression, following molecular breast cancer subtypes were selected: luminal A, luminal B HER2-negative, luminal B HER2-positive, nonluminal HER2-positive and triple negative. Results. Median survival in patients with bone vs. other site of metastases was 56 vs. 37 months respectively (p = 0.0098). ER expression was more common in patients who did, compared with those who did not develop bone metastases (74.% vs. 45% respectively; p = 0.0001), whereas cytoplasmic overexpression of OPN (1.9% vs. 14% respectively; p = 0.002) and PTHrPR1 (16% vs. 34% respectively; p = 0.007) was more common in patients with other sites of metastases. The impact of ER and cytoplasmic OPN expression on the risk of bone dissemination was confirmed in the multivariate analysis (Table 1). Luminal A breast cancer subtype (43% vs. 23% respectively; p = 0.009) and luminal B HER2-positive (16% vs. 4.9%, respectively; p = 0.032) were more common among patients with bone dissemination, whereas triple negative tumors prevailed in patients with other sites of metastases (16% vs. 38%; p = 0.002). Median survival of patients with luminal A subtype was significantly longer than that with remaining subtypes (67 vs. 38 months respectively; p = 0.0004). Conclusions. These results suggest that ER expression and lack of OPN expression are independent factors predicting increased risk of bone dissemination in breast cancer patients. Bone metastases are specifically associated with luminal A and luminal B HER2-positive subtypes. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-13-03." @default.
• W2056173816 created "2016-06-24" @default.
• W2056173816 creator A5004874011 @default.
• W2056173816 creator A5007681106 @default.
• W2056173816 creator A5010760064 @default.
• W2056173816 creator A5015565939 @default.
• W2056173816 creator A5017484722 @default.
• W2056173816 creator A5021865141 @default.
• W2056173816 creator A5024737224 @default.
• W2056173816 creator A5029023211 @default.
• W2056173816 creator A5032445613 @default.
• W2056173816 creator A5035731654 @default.
• W2056173816 creator A5043679041 @default.
• W2056173816 creator A5045464653 @default.
• W2056173816 creator A5049601783 @default.
• W2056173816 creator A5049923289 @default.
• W2056173816 creator A5050442240 @default.
• W2056173816 creator A5051552088 @default.
• W2056173816 creator A5059141227 @default.
• W2056173816 creator A5059590134 @default.
• W2056173816 creator A5060888272 @default.
• W2056173816 creator A5065273151 @default.
• W2056173816 creator A5066079103 @default.
• W2056173816 creator A5080769223 @default.
• W2056173816 creator A5081597399 @default.
• W2056173816 date "2012-12-15" @default.
• W2056173816 modified "2023-10-15" @default.
• W2056173816 title "Abstract P3-13-03: Molecular factors associated with bone metastases in breast cancer patients" @default.
• W2056173816 doi "https://doi.org/10.1158/0008-5472.sabcs12-p3-13-03" @default.
• W2056173816 hasPublicationYear "2012" @default.
• W2056173816 type Work @default.
• W2056173816 sameAs 2056173816 @default.
• W2056173816 citedByCount "0" @default.
• W2056173816 crossrefType "proceedings-article" @default.
• W2056173816 hasAuthorship W2056173816A5004874011 @default.
• W2056173816 hasAuthorship W2056173816A5007681106 @default.
• W2056173816 hasAuthorship W2056173816A5010760064 @default.
• W2056173816 hasAuthorship W2056173816A5015565939 @default.
• W2056173816 hasAuthorship W2056173816A5017484722 @default.
• W2056173816 hasAuthorship W2056173816A5021865141 @default.
• W2056173816 hasAuthorship W2056173816A5024737224 @default.
• W2056173816 hasAuthorship W2056173816A5029023211 @default.
• W2056173816 hasAuthorship W2056173816A5032445613 @default.
• W2056173816 hasAuthorship W2056173816A5035731654 @default.
• W2056173816 hasAuthorship W2056173816A5043679041 @default.
• W2056173816 hasAuthorship W2056173816A5045464653 @default.
• W2056173816 hasAuthorship W2056173816A5049601783 @default.
• W2056173816 hasAuthorship W2056173816A5049923289 @default.
• W2056173816 hasAuthorship W2056173816A5050442240 @default.
• W2056173816 hasAuthorship W2056173816A5051552088 @default.
• W2056173816 hasAuthorship W2056173816A5059141227 @default.
• W2056173816 hasAuthorship W2056173816A5059590134 @default.
• W2056173816 hasAuthorship W2056173816A5060888272 @default.
• W2056173816 hasAuthorship W2056173816A5065273151 @default.
• W2056173816 hasAuthorship W2056173816A5066079103 @default.
• W2056173816 hasAuthorship W2056173816A5080769223 @default.
• W2056173816 hasAuthorship W2056173816A5081597399 @default.
• W2056173816 hasConcept C121608353 @default.
• W2056173816 hasConcept C126322002 @default.
• W2056173816 hasConcept C129470790 @default.
• W2056173816 hasConcept C13373296 @default.
• W2056173816 hasConcept C142724271 @default.
• W2056173816 hasConcept C143998085 @default.
• W2056173816 hasConcept C170493617 @default.
• W2056173816 hasConcept C193270364 @default.
• W2056173816 hasConcept C204232928 @default.
• W2056173816 hasConcept C2780804394 @default.
• W2056173816 hasConcept C502942594 @default.
• W2056173816 hasConcept C530470458 @default.
• W2056173816 hasConcept C71924100 @default.
• W2056173816 hasConcept C84606932 @default.
• W2056173816 hasConcept C98717036 @default.
• W2056173816 hasConceptScore W2056173816C121608353 @default.
• W2056173816 hasConceptScore W2056173816C126322002 @default.
• W2056173816 hasConceptScore W2056173816C129470790 @default.
• W2056173816 hasConceptScore W2056173816C13373296 @default.
• W2056173816 hasConceptScore W2056173816C142724271 @default.
• W2056173816 hasConceptScore W2056173816C143998085 @default.
• W2056173816 hasConceptScore W2056173816C170493617 @default.
• W2056173816 hasConceptScore W2056173816C193270364 @default.
• W2056173816 hasConceptScore W2056173816C204232928 @default.
• W2056173816 hasConceptScore W2056173816C2780804394 @default.
• W2056173816 hasConceptScore W2056173816C502942594 @default.
• W2056173816 hasConceptScore W2056173816C530470458 @default.
• W2056173816 hasConceptScore W2056173816C71924100 @default.
• W2056173816 hasConceptScore W2056173816C84606932 @default.
• W2056173816 hasConceptScore W2056173816C98717036 @default.
• W2056173816 hasLocation W20561738161 @default.
• W2056173816 hasOpenAccess W2056173816 @default.
• W2056173816 hasPrimaryLocation W20561738161 @default.
• W2056173816 hasRelatedWork W1931094976 @default.
• W2056173816 hasRelatedWork W1963551677 @default.
• W2056173816 hasRelatedWork W1970039719 @default.
• W2056173816 hasRelatedWork W2008102732 @default.
• W2056173816 hasRelatedWork W2021795591 @default.
• W2056173816 hasRelatedWork W2116986258 @default.
• W2056173816 hasRelatedWork W2260566619 @default.
• W2056173816 hasRelatedWork W2282652962 @default.
• W2056173816 hasRelatedWork W2286156731 @default.
• W2056173816 hasRelatedWork W2312533745 @default.

• next